EMA CHMP issues negative opinion on Cessatech partner Proveca’s KemSu nasal spray filing

• Cessatech reported a negative CHMP opinion on Proveca’s EU PUMA application for CT001/KemSu, a ketamine-sufentanil nasal spray for acute pediatric pain.
• Proveca plans to seek a re-examination under EMA procedures, extending the review by several months.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cessatech A/S published the original content used to generate this news brief via Cision (Ref. ID: 20260724:BIT:1534:0) on July 24, 2026, and is solely responsible for the information contained therein.